{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:09:10Z","timestamp":1790629750411,"version":"4.1.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803035"],"award-info":[{"award-number":["81803035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572946"],"award-info":[{"award-number":["81572946"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703036"],"award-info":[{"award-number":["81703036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00852","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:22:40Z","timestamp":1567470160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications"],"prefix":"10.3389","volume":"9","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.biopha.2016.12.021","article-title":"Role of protease and protease inhibitors in cancer pathogenesis and treatment","volume":"86","author":"Eatemadi","year":"2017","journal-title":"Biomed Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","article-title":"New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin","volume":"661","author":"Fujii","year":"1981","journal-title":"Biochim Biophys Acta."},{"key":"B6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1254\/jjp.41.155","article-title":"Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats","volume":"41","author":"Iwaki","year":"1986","journal-title":"Jpn J Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","article-title":"Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies","volume":"109","author":"Minakata","year":"2019","journal-title":"Int J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000420222","article-title":"Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration","volume":"93","author":"Ohtake","year":"1991","journal-title":"Contrib Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.anl.2006.12.002","article-title":"Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma","volume":"34","author":"Yamashita","year":"2007","journal-title":"Auris Nasus Larynx."},{"key":"B10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12272-017-0996-9","article-title":"Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells","volume":"41","author":"Mander","year":"2018","journal-title":"Arch Pharm Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.intimp.2017.10.016","article-title":"Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells","volume":"54","author":"Homma","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/cncr.22658","article-title":"Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death","volume":"109","author":"Uwagawa","year":"2007","journal-title":"Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00534-011-0390-9","article-title":"Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition","volume":"18","author":"Fujiwara","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3892\/or.2010.843","article-title":"Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model","volume":"24","author":"Furukawa","year":"2010","journal-title":"Oncol Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2016.06.014","article-title":"Inhibition of the NF-kappaB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis","volume":"380","author":"Lu","year":"2016","journal-title":"Cancer Lett."},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10620-012-2311-4","article-title":"Inhibition of nuclear factor-kappaB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice","volume":"58","author":"Haruki","year":"2013","journal-title":"Dig Dis Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.surg.2013.05.037","article-title":"Inhibition of nuclear factor-kappaB enhances the antitumor effect of tumor necrosis factor-alpha gene therapy for hepatocellular carcinoma in mice","volume":"154","author":"Haruki","year":"2013","journal-title":"Surgery."},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2013.01.019","article-title":"Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-kappaB activation for pancreatic cancer","volume":"333","author":"Gocho","year":"2013","journal-title":"Cancer Lett."},{"key":"B19","unstructured":"Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation31738\n            UwagawaT\n            ChiaoPJ\n            GochoT\n            HiroharaS\n            MisawaT\n            YanagaK\n          19661331Anticancer Res.292009"},{"key":"B20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jamcollsurg.2012.09.016","article-title":"Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice","volume":"216","author":"Fujiwara","year":"2013","journal-title":"J Am Coll Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jss.2016.06.047","article-title":"New treatment strategy with nuclear factor-kappaB inhibitor for pancreatic cancer","volume":"206","author":"Horiuchi","year":"2016","journal-title":"J Surg Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/MPA.0b013e31820b9257","article-title":"Combination paclitaxel and inhibitor of nuclear factor kappaB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer","volume":"40","author":"Fujiwara","year":"2011","journal-title":"Pancreas."},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2015.10.034","article-title":"Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer","volume":"370","author":"Shirai","year":"2016","journal-title":"Cancer Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"E386","DOI":"10.3390\/cancers10100386","article-title":"Nafamostat mesilate enhances the radiosensitivity and reduces the radiation-induced invasive ability of colorectal cancer cells","volume":"10","author":"Sugano","year":"2018","journal-title":"Cancers."},{"key":"B25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jss.2013.06.003","article-title":"Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-kappaB activation","volume":"184","author":"Iwase","year":"2013","journal-title":"J Surg Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"E834","DOI":"10.3390\/ijms17060834","article-title":"Mast cell tryptase contributes to pancreatic cancer growth through promoting angiogenesis via activation of angiopoietin-1","volume":"17","author":"Guo","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1254\/jphs.FPJ05002X","article-title":"Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners","volume":"98","author":"Yoshii","year":"2005","journal-title":"J Pharmacol Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","article-title":"Noncanonical NF-kappaB signaling in health and disease","volume":"22","author":"Cildir","year":"2016","journal-title":"Trends Mol Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-kappaB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-kappaB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature18268","article-title":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","volume":"533","author":"Chen","year":"2016","journal-title":"Nature."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cell.2017.08.004","article-title":"NF-kappaB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer","volume":"170","author":"Grinberg-Bleyer","year":"2017","journal-title":"Cell."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ncb3240","article-title":"Non-canonical NF-kappaB signalling and ETS1\/2 cooperatively drive C250T mutant TERT promoter activation","volume":"17","author":"Li","year":"2015","journal-title":"Nat Cell Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"E2603","DOI":"10.3390\/ijms18122603","article-title":"Quinacrine inhibits ICAM-1 transcription by blocking DNA binding of the NF-kappaB subunit p65 and sensitizes human lung adenocarcinoma A549 cells to TNF-alpha and the fas ligand","volume":"18","author":"Harada","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.01.010","article-title":"VEGF\/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin","volume":"373","author":"Luo","year":"2016","journal-title":"Cancer Lett."},{"key":"B36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/1534735416642865","article-title":"Curcumol suppresses breast cancer cell metastasis by inhibiting MMP-9 via JNK1\/2 and Akt-dependent NF-kappaB signaling pathways","volume":"15","author":"Ning","year":"2016","journal-title":"Integr Cancer Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ags3.12025","article-title":"Glycogen synthase kinase-3beta activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells","volume":"2","author":"Haruki","year":"2018","journal-title":"Ann Gastroenterol Surg."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.03.009","article-title":"TRAF2 multitasking in TNF receptor-induced signaling to NF-kappaB, MAP kinases and cell death","volume":"116","author":"Borghi","year":"2016","journal-title":"Biochem Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.smim.2014.05.004","article-title":"Regulation of NF-kappaB by TNF family cytokines","volume":"26","author":"Hayden","year":"2014","journal-title":"Semin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0092-8674(03)00521-X","article-title":"Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes","volume":"114","author":"Micheau","year":"2003","journal-title":"Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"142359","DOI":"10.1155\/2015\/142359","article-title":"The role of mast cell specific chymases and tryptases in tumor angiogenesis","volume":"2015","author":"de Souza Junior","year":"2015","journal-title":"Biomed Res Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.yexcr.2014.11.014","article-title":"Tryptase, a novel angiogenic factor stored in mast cell granules","volume":"332","author":"Ribatti","year":"2015","journal-title":"Exp Cell Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy."},{"key":"B45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molimm.2014.04.001","article-title":"Human mast cell tryptase in biology and medicine","volume":"63","author":"Vitte","year":"2015","journal-title":"Mol Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/13543776.2017.1322064","article-title":"Tryptase inhibitors: a patent review","volume":"27","author":"Ni","year":"2017","journal-title":"Expert Opin Ther Pat."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3892\/ol.2018.8856","article-title":"Tryptase promotes breast cancer angiogenesis through PAR-2 mediated endothelial progenitor cell activation","volume":"16","author":"Qian","year":"2018","journal-title":"Oncol Lett."},{"key":"B48","doi-asserted-by":"publisher","first-page":"154702","DOI":"10.1155\/2014\/154702","article-title":"Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy","volume":"2014","author":"Ammendola","year":"2014","journal-title":"Biomed Res Int."},{"key":"B49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41467-017-00327-8","article-title":"Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B","volume":"8","author":"Wroblewski","year":"2017","journal-title":"Nat Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1172\/JCI94668","article-title":"Impaired angiopoietin\/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma","volume":"127","author":"Kim","year":"2017","journal-title":"J Clin Invest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1067\/msy.2001.115827","article-title":"Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis","volume":"130","author":"Keck","year":"2001","journal-title":"Surgery."},{"key":"B52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","article-title":"Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation","volume":"38","author":"Park","year":"2015","journal-title":"Int J Artif Organs."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1097\/MD.0000000000002392","article-title":"Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial","volume":"94","author":"Choi","year":"2015","journal-title":"Medicine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/annonc\/mdn640","article-title":"A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer","volume":"20","author":"Uwagawa","year":"2009","journal-title":"Ann Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/COC.0b013e31823a53b2","article-title":"Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer","volume":"36","author":"Uwagawa","year":"2013","journal-title":"Am J Clin Oncol."},{"key":"B56","unstructured":"Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy51216\n            FurukawaK\n            UwagawaT\n            IwaseR\n            HarukiK\n            FujiwaraY\n            GochoT\n          23155291Anticancer Res.322012"},{"key":"B57","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann Thorac Surg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","article-title":"Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy","volume":"39","author":"Makino","year":"2016","journal-title":"Int J Artif Organs."},{"key":"B59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/1744-9987.12357","article-title":"Safety and tolerability of nafamostat mesilate and heparin as anticoagulants in leukocytapheresis for ulcerative colitis: post hoc analysis of a large-scale, prospective, observational study","volume":"20","author":"Sawada","year":"2016","journal-title":"Ther Apher Dial."},{"key":"B60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.krcp.2015.10.003","article-title":"Cardiac arrest caused by nafamostat mesilate","volume":"35","author":"Kim","year":"2016","journal-title":"Kidney Res Clin Pract."},{"key":"B61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2353\/ajpath.2009.081093","article-title":"The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis","volume":"175","author":"Li","year":"2009","journal-title":"Am J Pathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0003-9861(91)90286-R","article-title":"The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175","volume":"284","author":"Poe","year":"1991","journal-title":"Arch Biochem Biophys."},{"key":"B63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbi.2016.03.019","article-title":"Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats","volume":"56","author":"Li","year":"2016","journal-title":"Brain Behav Immun."},{"key":"B64","first-page":"3223","article-title":"Effects of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection","volume":"46","author":"Inagaki","year":"1999","journal-title":"Hepatogastroenterology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/cas.13084","article-title":"Blockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant","volume":"107","author":"Waki","year":"2016","journal-title":"Cancer Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.intimp.2017.10.030","article-title":"Dexmedetomidine promotes liver regeneration in mice after 70% partial hepatectomy by suppressing NLRP3 inflammasome not TLR4\/NFkappaB","volume":"54","author":"Lv","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.humimm.2018.04.003","article-title":"Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions","volume":"79","author":"Kanangat","year":"2018","journal-title":"Hum Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"53518","DOI":"10.18632\/oncotarget.18591","article-title":"SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget."},{"key":"B69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2017.07.025","article-title":"An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling","volume":"85","author":"Lin","year":"2017","journal-title":"Eur J Cancer."},{"key":"B70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14728222.2018.1471137","article-title":"Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells","volume":"22","author":"Sasidharan Nair","year":"2018","journal-title":"Expert Opin Ther Targets."},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40425-017-0229-2","article-title":"Nuclear IRF-1 expression as a mechanism to assess Capability to express PD-L1 and response to PD-1 therapy in metastatic melanoma","volume":"5","author":"Smithy","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ijc.30834","article-title":"PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation","volume":"141","author":"Almozyan","year":"2017","journal-title":"Int J Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ccr.2014.07.027","article-title":"Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta\/MKK7 inhibitors","volume":"26","author":"Tornatore","year":"2014","journal-title":"Cancer Cell."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/cdd.2015.69","article-title":"NIK promotes tissue destruction independently of the alternative NF-kappaB pathway through TNFR1\/RIP1-induced apoptosis","volume":"22","author":"Boutaffala","year":"2015","journal-title":"Cell Death Differ."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-04-0084","article-title":"Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis","volume":"10","author":"Yoon","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e41347","DOI":"10.1371\/journal.pone.0041347","article-title":"Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations","volume":"7","author":"Brandi","year":"2012","journal-title":"PLoS ONE."},{"key":"B77","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00535-013-0834-x","article-title":"Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis","volume":"49","author":"Yuhara","year":"2014","journal-title":"J Gastroenterol."},{"key":"B78","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1023\/A:1015946123697","article-title":"Improvement in wound healing by epidermal growth factor (EGF) ointment","volume":"7","author":"Okumura","year":"1990","journal-title":"Pharm Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget."},{"key":"B80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12866-015-0593-3","article-title":"Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species","volume":"15","author":"Chiang","year":"2015","journal-title":"BMC Microbiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuropharm.2016.02.002","article-title":"Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1038\/srep05531","article-title":"Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition","volume":"4","author":"Chen","year":"2014","journal-title":"Sci Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4196\/kjpp.2016.20.5.539","article-title":"Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway","volume":"20","author":"Choi","year":"2016","journal-title":"Korean J Physiol Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"879326","DOI":"10.1155\/2014\/879326","article-title":"The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model","volume":"2014","author":"Lin","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B85","doi-asserted-by":"publisher","first-page":"R150","DOI":"10.1186\/ar3886","article-title":"Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis","volume":"14","author":"Inman","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1620\/tjem.237.45","article-title":"A synthetic serine protease inhibitor, nafamostat mesilate, is a drug potentially applicable to the treatment of ebola virus disease","volume":"237","author":"Nishimura","year":"2015","journal-title":"Tohoku J Exp Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T15:39:10Z","timestamp":1569080350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":87,"alternative-id":["10.3389\/fonc.2019.00852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"article-number":"852"}}